Search results for "ORPHAN DRUG|Designated/Withdrawn|Treatment for gastrointestinal stromal tumor" in comments (approximate match)
Showing 1 - 1 of 1 results
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Retaspimycin (IPI-504) was previously under development by manufacturer Infinity Pharmaceuticals in conjunction with MedImmune, a part of AstraZeneca. Retaspimycin is a small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative ...